Biocryst Pharmaceuticals Inc.

NASDAQ:BCRX   11:05:27 AM EDT
12.67
+0.15 (+1.20%)
Products

FDA Grants Orphan Drug Designation For Biocryst’S Alk-2 Inhibitor

Published: 08/31/2022 11:21 GMT
Biocryst Pharmaceuticals Inc. (BCRX) - FDA Grants Orphan Drug Designation for Biocryst’s Alk-2 Inhibitor, Bcx9250, for the Treatment of Fibrodysplasia Ossificans Progressiva.